Cannabis Indica

The T cell immune response against SARS-CoV-2

P Moss - Nature immunology, 2022 - nature.com
The adaptive immune response is a major determinant of the clinical outcome after SARS-
CoV-2 infection and underpins vaccine efficacy. T cell responses develop early and …

[HTML][HTML] Neutralizing monoclonal antibodies for treatment of COVID-19

PC Taylor, AC Adams, MM Hufford… - Nature Reviews …, 2021 - nature.com
Several neutralizing monoclonal antibodies (mAbs) to severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) have been developed and are now under evaluation in clinical …

[HTML][HTML] Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

RECOVERY Collaborative Group - Lancet (London, England), 2021 - ncbi.nlm.nih.gov
Background In this study, we aimed to evaluate the effects of tocilizumab in adult patients
admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods …

Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo …

VC Marconi, AV Ramanan, S de Bono… - The lancet Respiratory …, 2021 - thelancet.com
Background Baricitinib is an oral selective Janus kinase 1/2 inhibitor with known anti-
inflammatory properties. This study evaluates the efficacy and safety of baricitinib in …

Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial

E Kyriazopoulou, G Poulakou, H Milionis, S Metallidis… - Nature medicine, 2021 - nature.com
Early increase of soluble urokinase plasminogen activator receptor (suPAR) serum levels is
indicative of increased risk of progression of coronavirus disease 2019 (COVID-19) to …

Infectious Diseases Society of America Guidelines on the treatment and management of patients with coronavirus disease 2019 (COVID-19)

A Bhimraj, RL Morgan, AH Shumaker… - Clinical Infectious …, 2020 - academic.oup.com
Background There are many pharmacologic therapies that are being used or considered for
treatment of coronavirus disease 2019 (COVID-19). There is a need for frequently updated …

Therapeutic strategies for COVID-19: progress and lessons learned

G Li, R Hilgenfeld, R Whitley, E De Clercq - Nature Reviews Drug …, 2023 - nature.com
Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …

A guide to immunotherapy for COVID-19

FL van de Veerdonk, E Giamarellos-Bourboulis… - Nature medicine, 2022 - nature.com
Immune dysregulation is an important component of the pathophysiology of COVID-19. A
large body of literature has reported the effect of immune-based therapies in patients with …

Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis

P Domingo, I Mur, GM Mateo, M del Mar Gutierrez… - Jama, 2021 - jamanetwork.com
Importance Clinical trials assessing the efficacy of IL-6 antagonists in patients hospitalized
for COVID-19 have variously reported benefit, no effect, and harm. Objective To estimate the …

Pathophysiology of COVID-19-associated acute kidney injury

M Legrand, S Bell, L Forni, M Joannidis… - Nature Reviews …, 2021 - nature.com
Although respiratory failure and hypoxaemia are the main manifestations of COVID-19,
kidney involvement is also common. Available evidence supports a number of potential …

Leave a Reply